Scarica l'app Stockscreener
225.25
0.60%
-1.37
Ascendis Pharma A S Borsa (ASND) Ultime notizie
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - Zacks Investment Research
Ascendis Pharma (NasdaqGS:ASND) Stock Price - Simply Wall Street
Ascendis Pharma (ASND) Authorizes $400M Share Buyback - finance.yahoo.com
Ascendis Pharma (NASDAQ: ASND) board okays discretionary $400M share buyback - Stock Titan
Ascendis Pharma Authorizes Up to $400 Million Share Repurchase Program - Quiver Quantitative
Ascendis Announces Planned $400 Million Share Repurchase Program - GlobeNewswire
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Yahoo Finance
Ascendis Pharma (ASND) ReACHin Data Keeps The Bull Case Alive As Valuation Questions Linger - simplywall.st
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data By Investing.com - Investing.com Nigeria
Ascendis Pharma (NASDAQ: ASND) Issues 29,380 Employee Warrants at $270.09 Exercise Price - Kalkine Media
Insider Decision: Mads Bodenhoff Offloads $810K Worth Of Ascendis Pharma Stock - Benzinga
Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy - Investing.com
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com UK
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data - investing.com
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data - Investing.com
BMO reiterates Ascendis Pharma stock rating on infant trial data - investing.com
BMO reiterates Ascendis Pharma stock rating on infant trial data By Investing.com - Investing.com India
BMO reiterates Ascendis Pharma stock rating on infant trial data By Investing.com - Investing.com Canada
BMO reiterates Ascendis Pharma stock rating on infant trial data - Investing.com
Ascendis Pharma SVP Mads Bodenhoff Exercises Warrants and Sells 3,000 Shares on September 8, 2026 - Kalkine Media
Early infant trial hints at spine and growth gains, Ascendis Pharma (NASDAQ: ASND) says - Stock Titan
Ascendis Pharma SVP & Pao Sold Shares Worth Over $810K - TradingView
Ascendis Pharma (ASND) officer cashes 3K warrants, sells matching shares - Stock Titan
Ascendis Pharma (NASDAQ: ASND) prices new employee warrants at $270.09 - Stock Titan
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 - GlobeNewswire
Ascendis Pharma (NASDAQ:ASND): A Fitting Candidate for Affordable Growth Investors - ChartMill
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Yahoo Finance
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
Ascendis Pharma (NASDAQ: ASND) officer lines up 3,000-ADS sale for 2026 - Stock Titan
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - finance.yahoo.com
Ascendis to Present Navepegritide Infant Trial Data at ESPE 2026 - The Clinical Trial Vanguard
Ascendis Pharma A/S Trade Ideas — HAM:A710 - TradingView
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 - The Manila Times
Ascendis Pharma to Present Sentinel Cohort Data from reACHin Trial of TransCon CNP at ESPE 2026 - Quiver Quantitative
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 - GlobeNewswire
Ascendis Pharma A/S (ASND) Stock Analysis: Unveiling a 16.35% Potential Upside for Investors - DirectorsTalk Interviews
Ascendis Pharma (ASND) Could Be 14% Undervalued Following Yorvipath Reimbursement Progress - simplywall.st
Ascendis Pharma (ASND) Reimbursement Win Puts Its Fair Value Narrative Back In Focus - Yahoo Finance
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing - Yahoo Finance
Ascendis Pharma Director Lars Holtug Executes Sale of 236 Shares at $264.13 Each - Kalkine Media
Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $312 - Moomoo
Ascendis Pharma (ASND) director sells 236 shares in open-market trade - Stock Titan
Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND) - The Globe and Mail
Ascendis Pharma (ASND) director to sell shares for taxes - Stock Titan
Oppenheimer Adjusts Price Target on Ascendis Pharma to $312 From $304, Maintains Outperform Rating - marketscreener.com
Stifel Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $326 - Moomoo
Ascendis Pharma A/S (ASND) Institutional Ownership 2026 - MarketBeat
0.95%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):